Navigation Links
Bedford Laboratories™ to Begin Shipping Topotecan Hydrochloride for Injection, 4mg SD Vial
Date:4/18/2011

BEDFORD, Ohio,  April 18, 2011 /PRNewswire/ -- Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Topotecan Hydrochloride for Injection, 4 mg (base)/vial to its diverse portfolio.  Topotecan is AP Bioequivalent to the reference listed drug Hycamtin® (topotecan HCl) for injection by GlaxoSmithKline. Topotecan Hydrochloride for Injection is indicated for the treatment of metastic carcinoma of the ovary after failure of initial or subsequent chemotherapy.  Additionally, this product is used to treat small cell lung cancer. It is used in combination with cisplatin to treat cancer of the cervix, which cannot be treated with surgery or radiation therapy.

(Logo: http://photos.prnewswire.com/prnh/20070809/CLTH157LOGO)

Bedford Laboratories Topotecan Hydrochloride for Injection, 4 mg (base)/vial is sold individually and is latex free, UPC bar coded and preservative free.  This launch is an example of how Bedford Laboratories goes Beyond, Above-and-Beyond to provide our customers with pharmaceutical products that improve people's health and quality of life.

Prescribing information is available upon request from the Bedford Laboratories' professional services department at 800.521.5169, or from the company's web site, www.bedfordlabs.com.

About Bedford Laboratories

Bedford Laboratories produces an extensive selection of critical-care and medically necessary medications, including oncology products, cardiac agents, anesthesia products and other therapeutic class injectables. We recognize the importance of making sure that physicians and patients have access to the products they need when they need them. At Bedford Laboratories, quality is paramount. We take the utmost care in producing a high-quality reliable product supply to the market.  

About Ben Venue Laboratories, Inc.

Ben Venue Laboratories, Inc. was founded in 1938 and is a leading contract manufacturer of highly complex, sterile injectable drug products for the global pharmaceutical industry. Ben Venue is located in Bedford, Ohio and employs more than 1,300 people.  For more information and current career opportunities, visit www.benvenue.com.

Ben Venue is a U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.  Please visit http://us.boehringer-ingelheim.com.

Hycamtin®   is a registered trademark of GlaxoSmithKline


'/>"/>
SOURCE Bedford Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bedford Laboratories™ to Begin Shipping Dactinomycin for Injection USP 500 mcg (0.5 mg)
2. Bedford Laboratories(TM) First To Manufacture Generic Indomethacin for Injection USP
3. Bedford Laboratories(TM) To Begin Shipping Fluconazole Injection
4. ThermoGenesis Announces Registration of Res-Q in India; Commercial Sales Expected to Begin in Current Quarter
5. Boston Scientific Begins International Clinical Trial Enrollment for INNOVA™ Self-Expanding Bare-Metal Stent System
6. FDA Accepts Investigational New Drug Application for ARI-3030MO; First in Man Clinical Trial to Begin During First Quarter of 2011
7. Texas Childrens Is First Pediatric Hospital To Begin Certification Process for SynCardias Total Artificial Heart
8. Bacterin International Announces Major Orthopedic Hospital Group to Begin Use of OsteoSponge®SC
9. Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
10. Endo Pharmaceuticals and Orion Corporation Begin Novel R&D Collaboration
11. Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Element™ Everolimus-Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... THOUSAND OAKS, Calif. , April 19, 2017 ... premium industrial buildings it is developing at Conejo ... California , to Atara Biotherapeutics, Inc. ... patients with severe and life-threatening diseases that have ... focus on allogeneic T-cell therapies for cancer, autoimmune ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... and Gynecology markets with innovative and proprietary products, will ... 31, 2017 after the market close on Tuesday, May ... a conference call and webcast to discuss its financial ... at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). ...
(Date:4/18/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 6.35% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
Breaking Medicine Technology:
(Date:4/29/2017)... ... April 29, 2017 , ... Natural Family Planning ... observe the naturally occurring signs and symptoms of a woman's menstrual cycle. ... , Natural family planning and fertility are special interests of Dr. Bazger’s. She ...
(Date:4/29/2017)... ... April 29, 2017 , ... Phytomer USA is pleased to introduce Jennifer Smith ... Manager, Smith’s role is to provide excellent customer service, support, training and knowledge to ... Smith comes to Phytomer with a wealth of industry experience including roles as spa ...
(Date:4/29/2017)... ... April 29, 2017 , ... More than half of ... are Americans doing in their leisure time that causes hearing loss? May 1 marks ... may be contributing to hearing loss, as well as schedule a hearing evaluation for ...
(Date:4/28/2017)... ... April 28, 2017 , ... An April 24th article on Yahoo! Beauty discusses ... with the help of a weight loss surgery. The woman, declaring “I will not hate ... been left following her dramatic weight loss. Dr. Feiz & Associates notes that, while it ...
(Date:4/28/2017)... ... April 28, 2017 , ... Accreditation Commission for Health Care ... of America (HCAOA). This agreement allows HCAOA members to receive special pricing on ... on Accreditation University (AU) educational resources that help prepare HCAOA members for ACHC ...
Breaking Medicine News(10 mins):